Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
The year 2021 -- that's when Gilead Sciences (NASDAQ: GILD) thinks its acquisition of Kite Pharma (NASDAQ: KITE) will start to pay off. When Gilead announced plans to buy Kite, the company stated that the deal was expected to be neutral to earnings by year three and accretive after that.
In one sense, though, Gilead's Kite Pharma acquisition has already paid for itself. How? For investors.
Image source: Getty Images.
Source: Fool.com